Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • NET Cancer Day 2022
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Research » NET trial results presented at European Cancer Congress 2015

NET trial results presented at European Cancer Congress 2015

  • October 6, 2015
The European Cancer Congress (ECC 2015) combined the efforts of the most important European oncology professionals with the aim of improving the prevention, diagnosis, treatment and care of cancer patients. Partner organisations included: ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPE representing a multidisciplinary approach to cancer treatment and care.

Held in Vienna on September 25-29 many of our NET Community, patients and clinicans, attended to hear about the much anticipated results of two International NET clinical trials.

NETTER-1 Clinical Trial

Professor Philippe Ruszniewski, MD, Head of the Department of Gastroenterology-Pancreatology, Beaujon Hospital, Clichy, France, who is also a Professor at Paris Diderot University, told the Congress that results of the NETTER-1 phase III trial of 177Lu-DOTATATE (Lutathera) show a Progression Free Survival that has never been shown before in this type of cancer. "Because these patients have a real unmet medical need, this is particularly pleasing for us," he says. 

Click on this link to read full details http://www.esmo.org/Conferences/European-Cancer-Congress-2015/News/Rare-cancer-responds-unusually-well-to-new-treatment-results-from-the-NETTER-1-trial

RADIANT – 4 Trial

An international team of researchers has shown that the use of the mTOR inhibitor [1], everolimus, can delay tumour growth among both gastrointestinal and lung NETs. This is particularly important for patients with the lung tumours, the researchers say, because there is currently no approved treatment for such cases. Results for the trial were presented by Professor Jame Yao of the MD Anderson Cancer Centre in Houston USA.

Click here for more details http://www.esmo.org/Conferences/European-Cancer-Congress-2015/News/Results-of-International-Trial-Show-Promise-in-Rare-Difficult-to-Treat-Cancer-results-from-the-RADIANT-4-trial

The Unicorn Foundation and the global NET Patient community is heartened by these results, and encourage greater collaboration and continued support of NET trials such as CONTROL NETs, to build the body of evidence for treatments in NETs.

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

World Cancer Day 2023

January 10, 2023

Support Groups Christmas Gatherings

December 20, 2022

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

December 14, 2022

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

December 14, 2022
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousUF Research at Cancer Nurses Society of Australia Congress
NextClinicians embrace global survey results at ANZNET MeetingNext

Related Posts

The Australian Cancer Plan

Shaping the future of cancer control together   We are pleased to send you this update on the Australian Cancer Plan, the first national 10-year

Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness

Read full report

Peter MacCallum Cancer Centre – Recruiting NET health professionals for International Delphi survey

Recruiting NET health professionals for International Delphi survey Development of a neuroendocrine tumour (NET) nutrition-risk screening tool to identify patients requiring nutrition intervention and education

Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms

Read full report

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative